Background: Although heart failure (HF) patients are known to experience repeated hospitalizations, most studies evaluated only time to first event. N -Terminal B-type natriuretic peptide (NT-proBNP) guided therapy has not convincingly been shown to improve HF-specific outcomes, and effects on recurrent all-cause hospitalization are uncertain. Therefore, we investigated the effect of NT-proBNP guided therapy on recurrent events in HF with the use of a time-between-events approach in a hypothesis-generating analysis.
Methods and Results: The Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized 499 HF patients, aged >= 60 years, left ventricular ejection fraction = 2 all-cause hospitalization events. Regarding HF hospitalization, 132 patients (57 NT-proBNP guided, 75 symptom-guided) experienced 1 and 122 patients (57 NT-proBNP guided, 65 symptom-guided) experienced events. NT-proBNP guided therapy was significant in preventing 2nd all-cause hospitalizations (hazard ratio [HR] 0.83; P =.01), in contrast to nonsignificant results in preventing 1st all-cause hospitalization events (HR 0.91; P =.35). This was not the case regarding HF hospitalization events (HR 0.85 [P =.14] vs HR 0.73 [P =.01]) The beneficial effect of NT-proBNP guided therapy was seen only in patients aged <75 years, and not in those aged years (interaction terms with P =.01 and P =.03 for all-cause hospitalization and HF hospitalization events, respectively).
Conclusion: NT-prciBNP guided therapy reduces the risk of recurrent events in patients <75 years of age. This included all-cause hospitalization by mainly reducing later events, adding knowledge to the neutral effect on this end point when shown using time-to-first-event analysis only.
- Journal Article
- Heart failure
- natriuretic peptides peptide
- recurrent events
- STANDARD MEDICAL THERAPY
- RECURRENT EVENTS